Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. These findings add to the limited and mixed evidence base surrounding cannabinoid therapies for fibromyalgia, suggesting that CBD alone may not be a reliable analgesic option for this condition. Patients and clinicians should weigh these results carefully when considering CBD as part of a fibromyalgia management plan.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomised controlled trial provides rigorous clinical evidence on CBD efficacy for fibromyalgia, a condition where conventional pharmacotherapy has limited effectiveness and patients frequently seek alternative treatments. The double-blind, placebo-controlled design addresses the significant evidence gap surrounding CBD use in fibromyalgia, enabling clinicians to make evidence-based recommendations rather than relying on anecdotal reports. Establishing CBD’s safety and efficacy profile in this population could inform treatment algorithms for fibromyalgia patients who are refractory to standard analgesics or unable to tolerate conventional medications.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomized controlled trial represents a methodologically rigorous attempt to establish efficacy for cannabidiol in fibromyalgia, a condition where patients frequently self-report symptom relief despite the evidence base remaining sparse. The single-center design and recruitment from a specialized outpatient clinic may limit generalizability to broader fibromyalgia populations, and the abstract truncation prevents full assessment of primary outcomes, follow-up duration, and potential confounders such as concurrent medications or prior cannabinoid exposure. Fibromyalgia’s well-documented placebo responsiveness is particularly relevant here, as pain conditions involving central sensitization frequently show robust placebo effects that can obscure true drug efficacy. If the study demonstrates CBD superiority over placebo with clinically meaningful effect sizes, it would provide welcome evidence to guide patient conversations; however, clinicians should remain cautious about interpreting null or marginal findings as definitive, given the heterogeneous nature of fibromyalgia and individual variability in cannabinoid metabolism